Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Nov;68(5):950–957. doi: 10.1038/bjc.1993.460

Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.

P Dreger 1, P Marquardt 1, T Haferlach 1, S Jacobs 1, T Mülverstedt 1, V Eckstein 1, M Suttorp 1, H Löffler 1, W Müller-Ruchholtz 1, N Schmitz 1
PMCID: PMC1968738  PMID: 7692921

Abstract

The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Since many patients with relapsed lymphoma are eligible for high-dose chemotherapy with autologous stem cell rescue, we were interested in the suitability of these second line regimens for mobilising peripheral blood progenitor cells (PBPC). The kinetics of PBPC were studied in 15 patients treated with Dexa-BEAM and granulocyte colony-stimulating factor (G-CSF). Leukocytes started to rise from < 0.5 nL-1 on day 18 (16-22) after Dexa-BEAM, and exceeded 10 nL-1 on day 20 (18-28). Peripheral blood CFU-GM peaked on day 21 (19-28) and declined slowly thereafter; the median leukocyte count was 18.7 nL-1 (12.2-60) on the day of CFU-GM-peak. The maximum number of CFU-GM circulating in peripheral blood was inversely correlated to the duration of leukopenia after Dexa-BEAM. Measurement of CD34+ cells with the monoclonal antibody 8G12-PE (HPCA-2) predicted the number of CFU-GM precisely in both peripheral blood and leukapheresis products (r = 0.90-0.95). Two to six leukapheresis procedures yielded 6.39 x 10(8) mononuclear cells kg-1 (1.82-13.49) containing 44.4 x 10(4) CFU-GM kg-1 (2.2-213.8). Immunophenotypical analysis revealed that the percentage of CD19+ B cells was very low in all collection products (less than 1%). Nine patients were autografted with PBPC (15.4-213.8 x 10(4) CFU-GM kg-1) after myeloablative chemotherapy and experienced rapid and sustained engraftment (Platelets > 50 nL-1 on day +13 [9-22]). We conclude that PBPC can be mobilised effectively by Dexa-BEAM plus G-CSF. An adequate timing of PBPC collection (when the leukocyte count has exceeded 10 nL-1) and evaluation of the progenitor content of the leukapheresis products with 8G12-PE will allow to minimise the number of leukaphereses.

Full text

PDF
950

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aotsuka N., Asai T., Oh H., Yoshida S., Itoh K., Sato T. Lymphocyte subset reconstitution following human allogeneic bone marrow transplantation: differences between engrafted patients and graft failure patients. Bone Marrow Transplant. 1991 Nov;8(5):345–349. [PubMed] [Google Scholar]
  2. Ault K. A., Antin J. H., Ginsburg D., Orkin S. H., Rappeport J. M., Keohan M. L., Martin P., Smith B. R. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med. 1985 Jun 1;161(6):1483–1502. doi: 10.1084/jem.161.6.1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bender J. G., Williams S. F., Myers S., Nottleman D., Lee W. J., Unverzagt K. L., Walker D., To L. B., Van Epps D. E. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation. Bone Marrow Transplant. 1992 Sep;10(3):281–285. [PubMed] [Google Scholar]
  4. Brugger W., Bross K., Frisch J., Dern P., Weber B., Mertelsmann R., Kanz L. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood. 1992 Mar 1;79(5):1193–1200. [PubMed] [Google Scholar]
  5. Chopra R., Linch D. C., McMillan A. K., Blair S., Patterson K. G., Moir D., Richards J. D., Cervi P., Kinsey S., Goldstone A. H. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol. 1992 Jun;81(2):197–202. doi: 10.1111/j.1365-2141.1992.tb08207.x. [DOI] [PubMed] [Google Scholar]
  6. Civin C. I., Strauss L. C., Fackler M. J., Trischmann T. M., Wiley J. M., Loken M. R. Positive stem cell selection--basic science. Prog Clin Biol Res. 1990;333:387–402. [PubMed] [Google Scholar]
  7. DeLuca E., Sheridan W. P., Watson D., Szer J., Begley C. G. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer. 1992 Nov;66(5):893–899. doi: 10.1038/bjc.1992.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dreger P., Grelle K., Eckstein V., Suttorp M., Müller-Ruchholtz W., Löffler H., Schmitz N. Granulocyte-colony-stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation. Br J Haematol. 1993 Jan;83(1):7–13. doi: 10.1111/j.1365-2141.1993.tb04623.x. [DOI] [PubMed] [Google Scholar]
  9. Dreger P., Suttorp M., Haferlach T., Löffler H., Schmitz N., Schroyens W. Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood. 1993 Mar 1;81(5):1404–1407. [PubMed] [Google Scholar]
  10. Dührsen U., Villeval J. L., Boyd J., Kannourakis G., Morstyn G., Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988 Dec;72(6):2074–2081. [PubMed] [Google Scholar]
  11. Emminger W., Emminger-Schmidmeier W., Höcker P., Gerhartl C., Kundi M., Gadner H. The median daily increment of leukocytes during hematopoietic recovery reflects the myeloid progenitor cell yield during leukapheresis in children. Bone Marrow Transplant. 1990 Jun;5(6):419–424. [PubMed] [Google Scholar]
  12. Gianni A. M., Siena S., Bregni M., Tarella C., Stern A. C., Pileri A., Bonadonna G. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989 Sep 9;2(8663):580–585. doi: 10.1016/s0140-6736(89)90711-3. [DOI] [PubMed] [Google Scholar]
  13. Haas R., Hohaus S., Egerer G., Ehrhardt R., Witt B., Hunstein W. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant. 1992 Jun;9(6):459–465. [PubMed] [Google Scholar]
  14. Hardingham J. E., Kotasek D., Sage R. E., Dobrovic A., Gooley T., Dale B. M. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant. 1993 Jan;11(1):15–20. [PubMed] [Google Scholar]
  15. Janssen W. E., Farmelo M. J., Lee C., Smilee R., Kronish L., Elfenbein G. J. The CD34+ cell fraction in bone marrow and blood is not universally predictive of CFU-GM. Exp Hematol. 1992 May;20(4):528–530. [PubMed] [Google Scholar]
  16. Kessinger A., Armitage J. O., Smith D. M., Landmark J. D., Bierman P. J., Weisenburger D. D. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood. 1989 Sep;74(4):1260–1265. [PubMed] [Google Scholar]
  17. Kiesel S., Pezzutto A., Körbling M., Haas R., Schulz R., Hunstein W., Dörken B. Autologous peripheral blood stem cell transplantation: analysis of autografted cells and lymphocyte recovery. Transplant Proc. 1989 Feb;21(1 Pt 3):3084–3088. [PubMed] [Google Scholar]
  18. Martin P. J. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant. 1990 Nov;6(5):283–289. [PubMed] [Google Scholar]
  19. Matsunaga T., Sakamaki S., Kohgo Y., Ohi S., Hirayama Y., Niitsu Y. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant. 1993 Feb;11(2):103–108. [PubMed] [Google Scholar]
  20. Mitsuyasu R. T., Champlin R. E., Gale R. P., Ho W. G., Lenarsky C., Winston D., Selch M., Elashoff R., Giorgi J. V., Wells J. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med. 1986 Jul;105(1):20–26. doi: 10.7326/0003-4819-105-1-20. [DOI] [PubMed] [Google Scholar]
  21. Philip T., Armitage J. O., Spitzer G., Chauvin F., Jagannath S., Cahn J. Y., Colombat P., Goldstone A. H., Gorin N. C., Flesh M. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987 Jun 11;316(24):1493–1498. doi: 10.1056/NEJM198706113162401. [DOI] [PubMed] [Google Scholar]
  22. Richman C. M., Weiner R. S., Yankee R. A. Increase in circulating stem cells following chemotherapy in man. Blood. 1976 Jun;47(6):1031–1039. [PubMed] [Google Scholar]
  23. Schmitz N., Gassmann W., Rister M., Johannson W., Suttorp M., Brix F., Holthuis J. J., Heit W., Hertenstein B., Schaub J. Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. Blood. 1988 Nov;72(5):1567–1573. [PubMed] [Google Scholar]
  24. Schmitz N., Glass B., Dreger P., Haferlach T., Horst H. A., Ollech-Chwoyka J., Suttorp M., Gassmann W., Löffler H. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol. 1993 May;66(5):251–256. doi: 10.1007/BF01738475. [DOI] [PubMed] [Google Scholar]
  25. Sheridan W. P., Begley C. G., Juttner C. A., Szer J., To L. B., Maher D., McGrath K. M., Morstyn G., Fox R. M. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992 Mar 14;339(8794):640–644. doi: 10.1016/0140-6736(92)90795-5. [DOI] [PubMed] [Google Scholar]
  26. Siena S., Bregni M., Brando B., Belli N., Ravagnani F., Gandola L., Stern A. C., Lansdorp P. M., Bonadonna G., Gianni A. M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood. 1991 Jan 15;77(2):400–409. [PubMed] [Google Scholar]
  27. Siena S., Bregni M., Brando B., Ravagnani F., Bonadonna G., Gianni A. M. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1989 Nov 1;74(6):1905–1914. [PubMed] [Google Scholar]
  28. Socinski M. A., Cannistra S. A., Elias A., Antman K. H., Schnipper L., Griffin J. D. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28;1(8596):1194–1198. doi: 10.1016/s0140-6736(88)92012-0. [DOI] [PubMed] [Google Scholar]
  29. Teshima T., Harada M., Takamatsu Y., Makino K., Taniguchi S., Inaba S., Kondo S., Tanaka T., Akashi K., Minamishima I. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant. 1992 Sep;10(3):215–220. [PubMed] [Google Scholar]
  30. To L. B., Davy M. L., Haylock D. N., Dyson P. G., Thorp D., Juttner C. A. Autotransplantation using peripheral blood stem cells mobilized by cyclophosphamide. Bone Marrow Transplant. 1989 Sep;4(5):595–596. [PubMed] [Google Scholar]
  31. To L. B., Dyson P. G., Juttner C. A. Cell-dose effect in circulating stem-cell autografting. Lancet. 1986 Aug 16;2(8503):404–405. doi: 10.1016/s0140-6736(86)90096-6. [DOI] [PubMed] [Google Scholar]
  32. To L. B., Juttner C. A. Peripheral blood stem cell autografting: a new therapeutic option for AML? Br J Haematol. 1987 Jul;66(3):285–288. doi: 10.1111/j.1365-2141.1987.tb06911.x. [DOI] [PubMed] [Google Scholar]
  33. To L. B., Roberts M. M., Haylock D. N., Dyson P. G., Branford A. L., Thorp D., Ho J. Q., Dart G. W., Horvath N., Davy M. L. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992 Apr;9(4):277–284. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES